Kerry Horgan

1.3k total citations
13 papers, 962 citations indexed

About

Kerry Horgan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Kerry Horgan has authored 13 papers receiving a total of 962 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Hepatology. Recurrent topics in Kerry Horgan's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and HER2/EGFR in Cancer Research (3 papers). Kerry Horgan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and HER2/EGFR in Cancer Research (3 papers). Kerry Horgan collaborates with scholars based in United States, United Kingdom and Canada. Kerry Horgan's co-authors include Andrew X. Zhu, Alona Muzikansky, Lawrence S. Blaszkowsky, Pankaj Bhargava, Keith Stuart, David P. Ryan, Peter C. Enzinger, Jeffrey W. Clark, Susan Sheehan and Charles S. Fuchs and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Kerry Horgan

13 papers receiving 946 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kerry Horgan United States 9 470 353 276 257 250 13 962
Jie Mei China 18 525 1.1× 263 0.7× 177 0.6× 221 0.9× 211 0.8× 51 898
Bolorsukh Gansukh United States 6 421 0.9× 261 0.7× 164 0.6× 204 0.8× 156 0.6× 8 847
Minke He China 14 799 1.7× 234 0.7× 412 1.5× 148 0.6× 313 1.3× 41 1.1k
Vincenzo Dadduzio Italy 18 297 0.6× 451 1.3× 145 0.5× 164 0.6× 196 0.8× 39 834
Michele Basso Italy 18 292 0.6× 521 1.5× 115 0.4× 177 0.7× 150 0.6× 47 839
Anna Kan China 16 361 0.8× 275 0.8× 151 0.5× 331 1.3× 157 0.6× 38 927
Xiaochu Yan China 13 214 0.5× 289 0.8× 69 0.3× 254 1.0× 184 0.7× 33 801
A. Baldan Italy 7 647 1.4× 137 0.4× 167 0.6× 170 0.7× 162 0.6× 10 862
K. G Mamontov United States 3 699 1.5× 465 1.3× 286 1.0× 107 0.4× 153 0.6× 7 960
Ken Takasaki Japan 10 397 0.8× 173 0.5× 88 0.3× 207 0.8× 256 1.0× 15 808

Countries citing papers authored by Kerry Horgan

Since Specialization
Citations

This map shows the geographic impact of Kerry Horgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry Horgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry Horgan more than expected).

Fields of papers citing papers by Kerry Horgan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry Horgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry Horgan. The network helps show where Kerry Horgan may publish in the future.

Co-authorship network of co-authors of Kerry Horgan

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry Horgan. A scholar is included among the top collaborators of Kerry Horgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry Horgan. Kerry Horgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Taplin, Mary‐Ellen, Emmanuel S. Antonarakis, Karen J. Ferrante, et al.. (2017). Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 5005–5005. 20 indexed citations
3.
Antonarakis, Emmanuel S., Johann S. de Bono, Karen J. Ferrante, et al.. (2016). Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).. Journal of Clinical Oncology. 34(15_suppl). TPS5085–TPS5085. 2 indexed citations
4.
Ko, Andrew H., James H. Murray, Kerry Horgan, et al.. (2016). A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology. 34(4_suppl). TPS481–TPS481. 10 indexed citations
5.
Holmes, Frankie A., Kristi McIntyre, Ian E. Krop, et al.. (2015). Abstract P3-11-03: A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer. Cancer Research. 75(9_Supplement). P3–11. 9 indexed citations
6.
7.
Bendell, J. C., María Alsina, Daniel W. Watkins, et al.. (2014). Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad. 1 indexed citations
8.
Zhu, Andrew X., Jeffrey A. Meyerhardt, Lawrence S. Blaszkowsky, et al.. (2009). Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. The Lancet Oncology. 11(1). 48–54. 229 indexed citations
9.
Blaszkowsky, Lawrence S., Theodore S. Hong, Andrew X. Zhu, et al.. (2009). A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer (LARC). Journal of Clinical Oncology. 27(15_suppl). 4106–4106. 4 indexed citations
10.
Zhu, Andrew X., Nagaraj-Setty Holalkere, Alona Muzikansky, Kerry Horgan, & Dushyant V. Sahani. (2008). Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma. The Oncologist. 13(2). 120–125. 132 indexed citations
11.
Zhu, Andrew X., Keith Stuart, Lawrence S. Blaszkowsky, et al.. (2007). Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 110(3). 581–589. 190 indexed citations
12.
Zhu, Andrew X., Lawrence S. Blaszkowsky, Peter C. Enzinger, et al.. (2006). Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. Journal of Clinical Oncology. 24(18_suppl). 14096–14096. 9 indexed citations
13.
Zhu, Andrew X., Lawrence S. Blaszkowsky, David P. Ryan, et al.. (2006). Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology. 24(12). 1898–1903. 302 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jie Mei Breakdown of academic impact, for papers by Bolorsukh Gansukh Breakdown of academic impact, for papers by Minke He Breakdown of academic impact, for papers by Vincenzo Dadduzio Breakdown of academic impact, for papers by Michele Basso Breakdown of academic impact, for papers by Anna Kan Breakdown of academic impact, for papers by Xiaochu Yan Breakdown of academic impact, for papers by A. Baldan Breakdown of academic impact, for papers by K. G Mamontov Breakdown of academic impact, for papers by Ken Takasaki
Rankless by CCL
2026